LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Lista de Ações・CytoSorbents Corp

CytoSorbents Corp

Fechado

SetorSaúde

0.47 4.44

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.4

Máximo

0.51

Indicadores-chave
By Trading Economics
Rendimento	368K -5.1M
Vendas	-370K 8.9M
EPS	-0.08
Margem de lucro	-57.863
Funcionários	129
EBITDA	648K -3M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+56.25% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-10M 29M
Abertura anterior	-3.97
Fecho anterior	0.47

Sentimento de Notícias

By Acuity

100%

319 / 344 Ranking em Healthcare

CytoSorbents Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de jun. de 2026, 23:22 UTC

Ganhos

Grandes Movimentos do Mercado

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 de jun. de 2026, 23:09 UTC

Ações em Alta

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 de jun. de 2026, 20:51 UTC

Ganhos

Costco Reports 15% Sales Growth in May

3 de jun. de 2026, 20:43 UTC

Ganhos

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 de jun. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 de jun. de 2026, 23:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 de jun. de 2026, 23:35 UTC

Conversa de Mercado

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 de jun. de 2026, 23:15 UTC

Conversa de Mercado

Ganhos

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 de jun. de 2026, 22:08 UTC

Ações em Alta

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 de jun. de 2026, 21:54 UTC

Conversa de Mercado

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 de jun. de 2026, 21:18 UTC

Ganhos

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 de jun. de 2026, 21:15 UTC

Ganhos

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 de jun. de 2026, 21:13 UTC

Ganhos

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 de jun. de 2026, 21:13 UTC

Ganhos

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 de jun. de 2026, 21:12 UTC

Ganhos

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 de jun. de 2026, 21:09 UTC

Ganhos

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 de jun. de 2026, 21:03 UTC

Ganhos

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 de jun. de 2026, 20:43 UTC

Ganhos

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 de jun. de 2026, 20:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 de jun. de 2026, 20:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 de jun. de 2026, 20:35 UTC

Ganhos

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 de jun. de 2026, 20:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 de jun. de 2026, 20:17 UTC

Ganhos

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 de jun. de 2026, 20:17 UTC

Ganhos

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 de jun. de 2026, 20:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 de jun. de 2026, 20:15 UTC

Ganhos

Broadcom 2Q Adj EPS $2.44 >AVGO

3 de jun. de 2026, 20:15 UTC

Ganhos

Broadcom 2Q EPS $1.91 >AVGO

3 de jun. de 2026, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

3 de jun. de 2026, 20:15 UTC

Ganhos

Broadcom 2Q Rev $22.19B >AVGO

Comparação entre Pares

Variação de preço

CytoSorbents Corp Previsão

Preço-alvo

By TipRanks

56.25% parte superior

Previsão para 12 meses

Média 0.75 USD 56.25%

Máximo 0.75 USD

Mínimo 0.75 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para CytoSorbents Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para CytoSorbents Corp - Dist nos últimos 3 meses.

Sentimento

By Acuity

319 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.